Springworks Therapeutics (SWTX) reported a Q4 net loss Thursday of $1.04 per share, narrowing from a net loss of $1.44 a year earlier.

Analysts polled by FactSet expected a loss of $0.71.

Net product revenue for the quarter ended Dec. 31 was $61.5 million. The previous year's numbers were not provided.

Three analysts surveyed by FactSet expected product revenue of $61.7 million.

The biopharmaceutical company held cash and cash equivalents worth $461.9 million as of Dec. 31. Two analysts polled by FactSet expected $466.8 million.

Shares of the company were up more than 10% in recent premarket activity.

Price: 61.80, Change: +6.07, Percent Change: +10.89